Clinical trials: sponsored by CSPC Ouyi Pharmaceutical Co., Ltd.
Painful Diabetic Neuropathy
A Study to Evaluate Pregabalin in Painful Diabetic Peripheral Neuropathy
This study is designed to evaluate the efficacy and safety of pregabalin extended-release tablets in the treatment of neuropathic pain associated with diabetic peripheral neuropathy.
- Trial name
- NCT06383702
- Testing
- pregabalin sustained-release tablets
- Volunteers
- 358 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Healthy Participants
Bioequivalence Study of Olaparib Tablets Under Fasting and Fed Conditions in Healthy Subjects
This Study is a Randomized, Open-Label, 2-formulation, Single-Dose, 2-Period Crossover Bioequivalence Study with a washout period of 7 days.
- Trial name
- NCT06360445
- Testing
- Olaparib Tablet test formulation 100mg, Olaparib Tablet reference formulation 100mg, Olaparib Tablet test formulation 150mg
- Where
- China
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Advanced Breast Cancer
A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011
The main purpose of this study is to evaluate the efficacy and safety in subjects with advanced breast cancer treated with SYHX2011
- Trial name
- NCT06354114
- Testing
- SYHX2011
- Where
- China
- Volunteers
- 80 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Advanced Breast Cancer
A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)
The main purpose of this study is to evaluate the efficacy and safety in patients with advanced breast cancer treated with SYHX2011 versus paclitaxel for injection (albumin-bound).
- Trial name
- NCT05753865
- Testing
- SYHX2011, Paclitaxel for injection (albumin-bound)
- Where
- China
- Volunteers
- 454 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Advanced Malignant Tumors
Dose Escalation and Expansion Study of SYH2043 in Patients With Advanced Malignant Tumors
The aim of this study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of SYH2043 in patients with advanced malignant tumors.
- Trial name
- NCT05728541
- Testing
- SYH2043
- Where
- China
- Volunteers
- 367 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Advanced Solid Tumors
A Study Evaluating SYHX2005 in the Treatment of Patients With Advanced Solid Tumors
This is a first-in-human study with the SYHX2005 tablet primarily designed to evaluate the safety and tolerability of SYHX2005 at increasing doses in patients with advanced solid tumors and for whom no standard of care exists.
- Trial name
- NCT05609019
- Testing
- SYHX2005
- Volunteers
- 139 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Advanced Breast Cancer
A Pharmacokinetic Comparison Study of SYHX2011 and Abraxane® in Patients With Advanced Breast Cancer
This is a multi-center, open-label, pharmacokinetic comparison study of SYHX2011 and Abraxane® in patients with advanced breast cancers after single IV infusion.
- Trial name
- NCT05274893
- Testing
- SYHX2011 and Abraxane®
- Volunteers
- 28 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Healthy Subjects
The Safety, Tolerability, and Pharmacokinetics of SYHX1901 Tablets in Chinese Healthy Subjects
This is a phase I clinical trial to evaluate the safety, tolerability and pharmacokinetic characteristics of single ascending doses and multiple ascending doses of SYHX1901 tablets in Chinese healthy subjects
- Trial name
- NCT04880512
- Testing
- SYHX 1901 tablets
- Where
- China
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic
Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
This is a multicenter, randomized, open-lable, parallel-controlled phase II study of irinotecan liposome injection-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated, metastatic…
- Trial name
- NCT05047991
- Testing
- Irinotecan Liposome Injection, Fluorouracil, Leucovorin
- Volunteers
- 153 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Advanced Pancreatic Cancer
Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer.
Randomized, Open-label, Single-dose, Two-sequence, Two-period, Crossover Bioequivalence Trial of Irinotecan Liposome Injection in Patients With Advanced Pancreatic Cancer.
- Trial name
- NCT04482257
- Testing
- Irinotecan Liposome Injection combined with 5-FU/LV
- Where
- China
- Volunteers
- 48 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.